Update On Cost-Effectiveness Evaluation Of LEQEMBI By Japan's Health Ministry Council
July 9 (Reuters) - Eisai Co Ltd 4523.T: EISAI: UPDATE ON COST-EFFECTIVENESS EVALUATION OF LEQEMBI BY JAPAN'S HEALTH MINISTRY COUNCIL EISAI: WILL CONTINUE TO SEEK FAIR EVALUATION OF VALUE THAT LEQEMBI BRINGS Source text: https://www.eisai.com/news/2025/pdf/enews202545pdf.pdf Further company coverage: 4523.T (Reporting by Kantaro Komiya) ((Kantaro.Komiya@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China